Efficacy and safety of Xuebijing injection in the treatment of vascular endothelial injury in sepsis patients: A meta-analysis

Objective: To systematically evaluate the efficacy and safety of Xuebijing injection in the treatment of vascular endothelial injury in sepsis, and to provide evidence-based reference for clinical medication. Methods: The randomized controlled trials of Xuebijing injection combined with conventional treatment (experimental group) versus conventional treatment (control group) for sepsis were collected by computer search of Chinese CNKI database, WANFANG database, and VIP database. Literature screening was performed according to the inclusion and exclusion criteria. According to the Cochrane International Collaboration Evaluator Workbook procedure, the quality evaluation and bias analysis were performed for the literatures included in the meta-analysis. Revman 5.3 software was used for systematic metaanalysis. Results: A total of 15 clinical randomized controlled trials with a total of 930 patients were included. Meta-analysis showed that Xuebijing injection combined with conventional therapy could reduce 28-day mortality in sepsis[OR=0.52,95％CI(0.38,0.71),P<0.0001], APACHE Ⅱ integral [WMD=-2.65,95％CI(-3.23, -2.08),P<0.00001]; be effective in decreasing D-dimer [WMD=-0.79,95％CI(-1.17,-0.40),P<0.0001], TNF-α[WMD=-36.71,95％ CI(-43.04,-30.39),P<0.00001], vWF[WMD=-15.94,95％CI(-27.60,-4.28),P=0.007],sEselectin[ WMD=-118.30,95％CI(-139.65,-96.95),P<0.00001], ESM-1[WMD=-135.44,95％ CI(-186.30,-84.57),P<0.00001], sTM[WMD=-56.46,95％CI(-66.39,-46.53),P<0.00001]; can effectively increase platelets [WMD=30.78,95％CI(25.65, 35.92),P